ArticleBiologics : targets & therapy2026

Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program.

Rajesh Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.